Model-based meta-analysis of progression-free survival in non-Hodgkin lymphoma patients

about

Model-based meta-analysis of progression-free survival in non-Hodgkin lymphoma patients

Item

http://www.wikidata.org/entity/Q41622226

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Model-based meta-analysis of progression-free survival in non-Hodgkin lymphoma patients

@en

type

Item

label

Model-based meta-analysis of progression-free survival in non-Hodgkin lymphoma patients

@en

prefLabel

Model-based meta-analysis of progression-free survival in non-Hodgkin lymphoma patients

@en

P1476

Model-based meta-analysis of progression-free survival in non-Hodgkin lymphoma patients

@en

P2093

Ahmed Hamed Salem

http://www.w3.org/2001/XMLSchema#string

Kevin J Freise

http://www.w3.org/2001/XMLSchema#string

Mengyao Li

http://www.w3.org/2001/XMLSchema#string

Nimita Dave

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International

P2860

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

Relationship between treatment effects on progression-free survival and overall survival in multiple myeloma: a systematic review and meta-analysis of published clinical trial data.

Rituximab retherapy in patients with relapsed aggressive B cell and mantle cell lymphoma

Identification of potential surrogate end points in randomized clinical trials of aggressive and indolent non-Hodgkin's lymphoma: correlation of complete response, time-to-event and overall survival end points

Relationship between progression-free survival and overall survival in chronic lymphocytic leukemia: a literature-based analysis.

Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology.

Use of rituximab in diffuse large B-cell lymphoma in the salvage setting.

Evaluation of progression-free survival as a surrogate endpoint for survival in chemotherapy and targeted agent metastatic colorectal cancer trials.

Meta-analysis for the association between overall survival and progression-free survival in gastrointestinal stromal tumor.

Outcomes and endpoints in cancer trials: bridging the divide.

P304

e7988

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

meta-analysis

P356

10.1097/MD.0000000000007988

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P5008

ScienceSource

P577

2017-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28858138

http://www.w3.org/2001/XMLSchema#string

P921

non-Hodgkin lymphoma

P932

5585532

http://www.w3.org/2001/XMLSchema#string